Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-17-045196
Filing Date
2017-08-25
Accepted
2017-08-25 16:30:13
Documents
7
Period of Report
2017-10-19
Effectiveness Date
2017-08-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A v472996_def14a.htm DEF 14A 224360
2 GRAPHIC line.gif GRAPHIC 43
3 GRAPHIC logo_protalix.jpg GRAPHIC 25457
4 GRAPHIC sig_yossi-maimon.jpg GRAPHIC 9221
5 GRAPHIC spacer.gif GRAPHIC 43
6 GRAPHIC v472996_proxycard-1.jpg GRAPHIC 926177
7 GRAPHIC v472996_proxycard-2.jpg GRAPHIC 317102
  Complete submission text file 0001144204-17-045196.txt   1986012
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 171052331
SIC: 2836 Biological Products, (No Diagnostic Substances)